ACTUATE THERAPEUTICS INC (ACTU) Fundamental Analysis & Valuation

NASDAQ:ACTU • US0050831009

Current stock price

1.82 USD
+0.1 (+5.81%)
Last:

This ACTU fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ACTU Profitability Analysis

1.1 Basic Checks

  • In the past year ACTU has reported negative net income.
  • ACTU had a negative operating cash flow in the past year.
ACTU Yearly Net Income VS EBIT VS OCF VS FCFACTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -158.36%, ACTU is not doing good in the industry: 84.88% of the companies in the same industry are doing better.
  • The Return On Equity of ACTU (-280.51%) is worse than 73.45% of its industry peers.
Industry RankSector Rank
ROA -158.36%
ROE -280.51%
ROIC N/A
ROA(3y)-425.7%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACTU Yearly ROA, ROE, ROICACTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 -5K -10K -15K -20K -25K

1.3 Margins

  • ACTU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACTU Yearly Profit, Operating, Gross MarginsACTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ACTU Health Analysis

2.1 Basic Checks

  • ACTU has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for ACTU has been reduced compared to a year ago.
ACTU Yearly Shares OutstandingACTU Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M 20M
ACTU Yearly Total Debt VS Total AssetsACTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • ACTU has an Altman-Z score of -16.03. This is a bad value and indicates that ACTU is not financially healthy and even has some risk of bankruptcy.
  • ACTU has a Altman-Z score of -16.03. This is amonst the worse of the industry: ACTU underperforms 81.20% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that ACTU is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.05, ACTU perfoms like the industry average, outperforming 41.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -16.03
ROIC/WACCN/A
WACCN/A
ACTU Yearly LT Debt VS Equity VS FCFACTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 2.39 indicates that ACTU has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.39, ACTU is doing worse than 72.67% of the companies in the same industry.
  • ACTU has a Quick Ratio of 2.39. This indicates that ACTU is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.39, ACTU is not doing good in the industry: 69.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
ACTU Yearly Current Assets VS Current LiabilitesACTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ACTU Growth Analysis

3.1 Past

  • ACTU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.80%, which is quite impressive.
EPS 1Y (TTM)22.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 30.86% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.98%
EPS Next 2Y-15.96%
EPS Next 3Y-9.25%
EPS Next 5Y30.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACTU Yearly Revenue VS EstimatesACTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
ACTU Yearly EPS VS EstimatesACTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ACTU Valuation Analysis

4.1 Price/Earnings Ratio

  • ACTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ACTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACTU Price Earnings VS Forward Price EarningsACTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACTU Per share dataACTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • ACTU's earnings are expected to decrease with -9.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.96%
EPS Next 3Y-9.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACTU Dividend Analysis

5.1 Amount

  • ACTU does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACTU Fundamentals: All Metrics, Ratios and Statistics

ACTUATE THERAPEUTICS INC

NASDAQ:ACTU (4/13/2026, 8:07:30 PM)

1.82

+0.1 (+5.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)05-15
Inst Owners55.4%
Inst Owner Change0%
Ins Owners4.6%
Ins Owner Change25.66%
Market Cap43.15M
Revenue(TTM)N/A
Net Income(TTM)-22.23M
Analysts82
Price Target25.5 (1301.1%)
Short Float %3.46%
Short Ratio9.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.82%
Min EPS beat(2)11.68%
Max EPS beat(2)27.97%
EPS beat(4)3
Avg EPS beat(4)9.93%
Min EPS beat(4)-3.43%
Max EPS beat(4)27.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)14%
EPS NQ rev (3m)14%
EPS NY rev (1m)5.28%
EPS NY rev (3m)8.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.45
P/tB 5.45
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.36%
ROE -280.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-425.7%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z -16.03
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y4.98%
EPS Next 2Y-15.96%
EPS Next 3Y-9.25%
EPS Next 5Y30.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.07%
OCF growth 3YN/A
OCF growth 5YN/A

ACTUATE THERAPEUTICS INC / ACTU Fundamental Analysis FAQ

What is the fundamental rating for ACTU stock?

ChartMill assigns a fundamental rating of 1 / 10 to ACTU.


What is the valuation status of ACTUATE THERAPEUTICS INC (ACTU) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACTUATE THERAPEUTICS INC (ACTU). This can be considered as Overvalued.


How profitable is ACTUATE THERAPEUTICS INC (ACTU) stock?

ACTUATE THERAPEUTICS INC (ACTU) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ACTUATE THERAPEUTICS INC?

The Earnings per Share (EPS) of ACTUATE THERAPEUTICS INC (ACTU) is expected to grow by 4.98% in the next year.